EPISODE · Mar 14, 2025 · 18 MIN
Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target
from BiotechTV - News · host BiotechTV
Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good Therapeutics, and how the follow-on company Bonum aims to test this approach more broadly. He describes how it works, and discusses the initial programs they have chosen, with a LAG3-IL2 being the most advanced.
Embed this episode
Ready to play
Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.